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Abstract
With easy chemical synthesis from its precursor, methamphetamine (MA) is now widespread in many countries. 
The abuse of methamphetamine is associated with several negative effects on health, because MA is a neurotoxin 
and a dangerous central nervous system stimulant. It changes levels of neurotransmitters in the brain, releasing 
dopamine and inhibiting nor epinephrine uptake which increases sympathetic nervous system activity and can 
lead to cardiac arrhythmia, hypertension and tachypnea. The consequences of MA abuse are clearly manifested 
in oral diseases (like “meth mouth”) which is characterised by extensive caries, teeth grinding with ensuing dental 
wear and trismus. The present review was designed to fill the gap in knowledge about methamphetamine abuse in 
the European Union (EU) and to illustrate the main clinical effects of   prolonged use. After describing the phar-
macology and systemic effects of methamphetamine and concentrating on its effects on the mouth, the present 
review compares the epidemiology and incidence of abuse in the world, particularly the USA and the EU.
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Introduction
Methamphetamine (MA) belongs to the amphetamine-
type stimulant (ATS) class of substances which includes 
two categories: drugs like amphetamine, methampheta-
mine and their correlates such as  fenetylline, methylphe-
nidate, phenmetrazine, cathinone and so on and “ecstasy-
type” drugs like MDMA, MDA and MDEA (1).
MA is a colourless, insoluble volatile oil. As a hydro-
chloride salt it is a bitter tasting, crystalline white pow-
der that is easily dissolved in water or alcohol and of-
ten used today as an illegal drug. Although it may be 
inhaled or injected, it is usually smoked, swallowed as 
a pill or dissolved in a drink because of its bitter taste. 
Popular names for methamphetamine in powder are: 
Crank, Crypto, Fire, Meth, Speed. MA powder needs to 
be purified into a large crystal to be smoked. Hence the 
names: Crystal Meth, Crystal Glass, Ice (2).
More powerful and easier to produce than ampheta-
mine,  MA was first synthesized in Japan in 1919  , and 
was widely used by all sides  in World War II to keep the 
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troops in a state of constant alertness. Indeed, Japanese 
kamikaze pilots received high doses before their suicide 
missions (3).  After various ups and downs (see Table 1), 
MA rapidly became popular in the USA in the 1990s and 
was introduced into Europe through the Czech Repub-
1919  Ephedrine was synthesized (Ogata, 1919). 
1920  Burroughs Wellcome patent as  chlorhydrate. 
1920-1930  Medical and paramedical use in Europe.  
1938 “Pervitin” production started  (Temmler Industry, Berlin, Germany). 
World War II  “Pervitin” distributed to German troops, “Philopon”  to the Japanese and  “Methedrine”  to the USA and UK armies. 
1945-1950 Legal sales of war surplus methamphetamine spreads use to 
civilians.  
1950-1960
Countries producing methamphetamine restrict sales. 
Organised crime sets up illegal sources and later starts 
production. 
1970 Methamphetamine used for cocaine detoxification. 
 Table 1. History of methamphetamine.
Source: EMCDDA- Europol joint publications-methampheta-mine. An European Union per-
spective in the global context.
 EMCDDA Lisbon 2009.
lic (1). It gives a false sense of well-being, energy and 
over-estimation of physical and mental capacities and 
leads to a state of collapse once its effect is over. Pro-
longed use leads to addiction in a series of stages which 
are characteristically described as the (2,4): “rush” i.e. 
the effect of smoked or injected MA which is associated 
with tachycardia, sweating and increased blood pres-
sure for about 30 minutes; “high”, i.e. a  hyper-reactive, 
arrogant attitude lasting for several hours; “binge” i.e. a 
long period of 3 to 15 days during which the addict tries 
to maintain a constant  “high” by ingesting higher and 
higher MA doses; “tweaking” or “itch”  which develops 
at the end of a binge, when high MA doses no longer 
produce a “rush” or a “high”. This addiction stage is 
associated with skin hyperesthesia and tactile halluci-
nations which mimic the presence of insects under the 
skin. The addict suffers from psychosis, insomnia, per-
secution mania and neglects personal hygiene. 
In the final stages of addiction, when new doses cannot 
be acquired, a few days lethargy is followed by recov-
ery characterized by organic wasting which prevents 
normal activities. Finally, after one or two months the 
addict experiences the onset of withdrawal symptoms 
with depression, dysphoria, fatigue and suicidal idea-
tion. 
MA abuse can also be summarized in three escalating 
stages: 
- Occasional or low-intensity use. The individual in-
gests MA pills or inhales powder to achieve “highs” or 
weight loss.
- Uncontrolled use. The individual smokes or inject MA 
to achieve rapid, intense effects, triggering essentially 
psychological addiction. 
- High-intensity use. The individual (“speed freak”) is 
psychologically and physically addicted, demanding 
higher and higher doses.
Abuse of MA is associated with several negative effects 
on health, particularly “Meth mouth”  which is char-
acterized by widespread caries, teeth grinding with 
ensuing dental wear, and lockjaw (2,4). Since almost 
all reports to date have focused on the links between 
MA abuse and oral damages in the USA, the present 
review was designed to fill the gap in knowledge about 
MA abuse in European Union (EU) countries. After de-
scribing the pharmacology and systemic effects of MA, 
concentrating on its effects on the mouth, the present 
review compares epidemiology and incidence of abuse 
in the USA and EU. 
Pharmacology
Figure 1 and Table 2 show the formula and chemical 
properties of MA which is a neurotoxin and, even in 
small doses,  a powerful central nervous system stimu-
lant. It changes levels of monoamines and neurotrans-
mitters in the brain, releasing dopamine and inhibiting 
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nor-epinephrine uptake which increases activity of the 
sympathetic nervous system and can lead to cardiac ar-
rhythmia, hypertension and tachypnea  (5,6).
After oral administration maximum plasma concentra-
tions are reached  in 2 or 3 hours but the effects manifest 
after only 20 minutes. With intravenous injection maxi-
mum plasma concentrations occur within 2 to 4 minutes 
(7). 
MA is metabolized by microsomal enzymes in the liver, 
but chronic use does not increase their number. It is oxi-
dized by part of  the P-450 cytochrome 2D6 isoenzyme 
and glucuronidized into one active metabolite (amphet-
amine) and two inactive metabolites (nor-ephedrine and 
p-hydroxyl-nor-ephedrine) (8). Excreted through blood 
and kidneys, it has a half-life of 8 to 30 hours, according 
to the urinary pH. When it ranges from 6 to 8, MA is 
cleared in about 12 hours, independently of the admin-
istration route  (7-9,10).
In habitual users MA markedly modifies the function of 
specific  cerebral areas like the prefrontal cortex and the 
caudal nucleus, particularly the “nucleus accumbens”, 
that are linked to emotions and memory (5). You can de-
velop a tolerance resulting from quick depletion of the 
availability of neurotransmitters which also contributes 
to the cause withdrawal crisis (10).
Short-term effects include euphoria, loquacity, over-
excitement, insomnia, tremors, tachypnea and lack of 
appetite (10,11) while over the long-term the user mani-
fests cognitive and emotional changes, violent behav-
iour, anxiety, paranoia, hallucinations, irritability and 
mood swings (5).
Overdose is associated with angina, dyspnoea, sweat-
ing, palpitations, nausea, vomiting, convulsions and 
hallucinations. More severe side effects are ventricular 
fibrillation, myocardial infarction, cardiovascular col-
lapse and high temperature. If not treated  promptly 
with  urine acidification, you may have even death (2).
Typical withdrawal symptoms are depression, anxiety, 
fatigue and irrepressible desire for the drug. If MA and 
cocaine withdrawal are associated the patient may have 
suicidal and homicidal tendencies and a severe sleep 
disorder. MA use during pregnancy can cause miscar-
riage or premature birth and, in the newborn, hypotro-
phy, congenital abnormalities, delayed development and 
withdrawal symptoms (12). 
Although amphetamine and its analogues were admin-
istered in the past to treat depression, attention deficit, 
obesity and narcolepsy, MA was always demonstrated 
to be too active and too dangerous. Even its analogues 
like for example methylphenidate causes side effects 
like hyperactivity, euphoria, loss of appetite, loquacity 
and increased libido (13) (Table 3).
Methamphetamine abuse and dental disease 
Several reports have linked MA abuse to oral pathol-
ogies. “Meth mouth” is the general term for rampant 
caries like “early childhood caries” (14-17). Lesions are 
localized on all smooth buccal surfaces and on proximal 
interfaces of the front teeth (2,4,13,15,18) (see Fig.1). 
Teeth are described as “blackened, stained, rotting, 
crumbling or falling apart” (19) and “the typical pattern 
of decay involves the facial and cervical areas of both 
the maxillary and mandibular teeth with eventual pro-
gression to frank coronal involvement” (3). 
Despite several clinical studies, the incidence of car-
ies in MA abusers has only recently been reported as 
greater  than  in the general population. A pilot study 
comparing 18 MA users and 18 controls  showed plaque 
and DMFT indices were much higher in users (20). In 
another report plaque, DMFS and dental calculus levels 
were significantly higher in 28  users than in 16 controls 
(21). In  yet another  investigation DMFS and S-OHI 
were significantly higher in a cohort of 58 young adult 
users than in the general population  (22).One study ob-
served that DMFT was significantly higher in 59 young 
adult prisoners who were MA users than in 40 control 
prisoners who were not and  demonstrated that dura-
Fig. 1. A clinical case of  initial “meth mouth” in a young drug ad-
dict.
IUPAC (2S)-N-metyl-1-phenyl-propan-2-amine
Formula C10H15N
Molecular 
Weight (u) 149,223 
Form Oily brown liquid 
Acid dissociation 
constant at 298.15 K 9,9 
Fusion Point 170-175°C (443,15 - 448,15 K) 
Boiling Point 300-305°C (573,15 - 578,15 K) 
LD50 (mg/kg)                                 15 
Table 2. Chemical properties of methamphetamine (MA).
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tion of use was the most significant predictor of “meth 
mouth” severity (23). In spite of these findings the high 
incidence of caries  does not appear useful in distin-
guishing between  users and non-users (24).
“Meth mouth” is hypothesized to be caused by a combi-
nation of MA-related mental and physiological changes 
such as xerostomia (dry mouth), long periods of poor 
mouth hygiene, and frequent ingestion of sugary, fizzy 
drinks (2,3,14-16). Additional factors might be the aci-
dic nature of MA (2-4,16) which, through contact with 
teeth after inhalation, might exert a caustic action (16).
Recent studies have provided evidence in support of 
some of these hypotheses. 
1. Ravenel et al.  observed no significant differences in 
saliva flow levels in 28 MA users and 16 controls but 
found saliva pH and buffer capacity tended to be lower 
in users, suggesting saliva quality played a key role in 
“meth mouth” (21). Some investigations confirmed the 
detrimental impact of long periods of poor oral hygiene 
and increased consumption of sugary drinks (20,22). In 
showing that “meth mouth” was similar in intravenous 
MA users Shetty et al. (19)  refuted the hypothesis that 
MA exerted a corrosive or acidic effect on teeth. Rather 
surprisingly, Brown et al.  (23) did not find concomi-
tant alcohol abuse was a significant risk factor for “meth 
mouth” severity in 50 prisoners who were MA users, 
which seems to suggest the MA mechanism of action is 
different to other illegal substances.  
2. The debate over whether  xerostomia (dry mouth) is as-
sociated with MA abuse is still open, with some reports 
claiming dry mouth is present  (2-4)  and others denying 
it  (22) on the basis of saliva flow analysis. Complaints of 
dry mouth might be subjective as 95% of 119 subjects in 
one study declared it was present (16) while 90% of 17 
patients in another did not complain of it (22).  
3. Excess dental wear  is mainly due to teeth grinding 
(2,4,25) and possibly para-functional  jaw activity, peri-
odontal or temporomandibular disorders (2,25). In 43 
MA users Richard and Brofeld  (26)  established an  in-
creased incidence in tooth wear, the severity of which 
varied with administration  route as the most advanced 
tooth wear was detected in patients who sniffed MA. 
Shetty et al. (19) found   tooth grinding (bruxism) or 
erosion in 22.3% of 301 patients (67 individuals).
The clinical signs of “meth mouth” do not differ from 
bad oral hygiene and dental destruction observed on 
other drugs abusers (e.g. heroin), but are faster to appear 
and more severe (22). One hypothesis is that the cor-
rosive effect of Ma and its derivatives can occur locally 
because of their excretion through the crevicular fluid.
Treating dental patients who are methampheta-
mine users 
Most MA users who attend a dental clinic do not admit 
they are users when giving their case history for fear 
of being judged or reported to the police. Consequently 
dentists should be trained to recognize the main signs 
and symptoms of MA abuse. After obtaining as much 
information on the patient’s medical and dental history 
as s/he will provide, dental surgeons should observe 
whether the patient has skin lesions on the arm which 
indicate intravenous use of illegal drugs and ask about 
sudden fever of unknown origin which might suggest 
the same.  Paranoid behaviour with mood swings, poor 
compliance and episodes of violence should be carefully 
assessed as they might also indicate addiction.  
Dentists should bear in mind that risk of acquiring and 
transmitting blood-borne diseases like HIV and hepati-
tis B and C is increased in MA users  because the MA-
induced high may be associated with lack of inhibition 
of risky sexual (27).
Mild 
Nausea, vomiting, abdominal pain, diarrhoea, palpitations, tremors, 
hyperreflexia, mydriasis, flushing or pallor, sweating, headache, 
restlessness, irritability, insomnia, xerostomia, bad taste, bruxism, 
trismus 
Moderate Hyperactivity, confusion, aggression, anxiety, hallucinations, muscle rigidity, tachycardia, hypertension, chest tightness, tachypnea, 
dyspnoea, mild pyrexia, dehydration 
Severe Delirium, hallucinations, paranoia, hyperpyrexia (>40°C), hypertension or hypotension, cardiac dysrhythmias, seizures, coma, renal failure 
associated with rhabdomyolysis 
Potentially fatal 
Ventricular fibrillation, myocardial infarction, acute cardiac failure, 
cerebrovascular accident (usually cerebral haemorrhage), extreme 
hyperthermia (may precipitate disseminated intravascular coagulation),  
repeated seizures, cerebral oedema with brainstem compression 
secondary to hypoxia or hyponatremia 
Table 3. Clinical signs and symptoms of acute methamphetamine toxicity.  
 Source: modified from Hamamoto and Rhodus (2). 
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General dental treatment for MA users should adhere 
to the following fundamental guidelines (2,3,11): if a 
patient shows signs of recent MA ingestion, only sup-
portive treatment should be given; the team should be 
ready to implement safety measures for itself and other 
patients should the MA user exhibit paranoid or violent 
behaviour; MA users who are “high” should not receive 
any dental treatment whatsoever until at least 6 hours 
have elapsed since the drug was taken, because sym-
pathomimetic effects at this stage are associated with a 
very high risk of myocardial ischemia and  arrhythmia; 
should dental treatment be needed, local anaesthetics 
should never contain adrenalin or noradrenalin because 
they can potentiate the sympathomimetic response to 
MA, which  could raise blood pressure excessively and 
cause a cerebral vascular accident or myocardial infarc-
tion; a general anaesthesia or sedation can cause sudden 
death in an MA user; since an increased respiratory rate 
(tachypnea) can lead to depressed respiration, the pa-
tient will require 100% oxygen and frequent heart rate 
and blood pressure check-ups; heart and lung resuscita-
tion apparatus should be readily available in case the 
patient suffers a cardiovascular collapse. 
Short notes of epidemiology
MA production is greatest in the Far East and South-
east Asia (China, the Philippines, Myanmar and Thai-
land), followed by North and Central America (the USA, 
Canada and Mexico) (17). MA appears to be mainly 
produced in Europe in the Czech Republic  but most is 
destined for the domestic market although some reaches 
Germany, Austria and Slovakia  (28). 
Ephedrine, pseudoephedrine and 1-phenyl-2-propanone 
(P-2-P o BMK) (Fig. 2) are the main MA precursors. 
MA is produced illegally by reducing ephedrine or 
pseudoephedrine with iodine, hypophosphite or am-
moniac ions while legal pharmaceutics are produced by 
reductive amination of P-2-P. Since ephedrine or pseu-
doephedrine are contained in drugs for human use they 
are excluded from the 111/2005 CE regulation which 
legislates for trade in drug precursors between the EU 
and non-EU countries.
Major problems with MA use have been referred by 
many countries including the USA, South-east Asia, the 
Pacific and Africa (28). The American Dental Associa-
tion (17) confirmed findings in the 2010 National Survey 
on Drug Use and Health, by stating that although MA 
use appears to be falling it is still a matter of concern. 
MA appears to be less extensively used in Europe than 
in the USA. Abuse show to peak in 2005-2007 and then 
decline in central (Czech Republic, Slovakia, Hungary 
and Slovenia) and northern (UK, Denmark, Norway, 
Finland and Sweden) Europe.  MA abuse is negligible in 
southern European countries and predominates among 
young adults (28). 
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